- Home
- ACET vs STRO Comparison
ACET vs STRO Comparison
Compare ACET & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- STRO
- Stock Information
- Founded
- ACET 1947
- STRO 2003
- Country
- ACET United States
- STRO United States
- Employees
- ACET N/A
- STRO N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACET Health Care
- STRO Health Care
- Exchange
- ACET Nasdaq
- STRO Nasdaq
- Market Cap
- ACET 60.5M
- STRO 69.1M
- IPO Year
- ACET N/A
- STRO 2018
- Fundamental
- Price
- ACET $0.72
- STRO $0.86
- Analyst Decision
- ACET Strong Buy
- STRO Hold
- Analyst Count
- ACET 7
- STRO 7
- Target Price
- ACET $5.60
- STRO $1.97
- AVG Volume (30 Days)
- ACET 679.5K
- STRO 390.7K
- Earning Date
- ACET 08-07-2025
- STRO 08-07-2025
- Dividend Yield
- ACET N/A
- STRO N/A
- EPS Growth
- ACET N/A
- STRO N/A
- EPS
- ACET N/A
- STRO N/A
- Revenue
- ACET N/A
- STRO $104,473,000.00
- Revenue This Year
- ACET N/A
- STRO $65.42
- Revenue Next Year
- ACET N/A
- STRO N/A
- P/E Ratio
- ACET N/A
- STRO N/A
- Revenue Growth
- ACET N/A
- STRO N/A
- 52 Week Low
- ACET $0.45
- STRO $0.52
- 52 Week High
- ACET $1.63
- STRO $4.80
- Technical
- Relative Strength Index (RSI)
- ACET 52.09
- STRO 52.41
- Support Level
- ACET $0.64
- STRO $0.83
- Resistance Level
- ACET $0.78
- STRO $0.83
- Average True Range (ATR)
- ACET 0.06
- STRO 0.07
- MACD
- ACET 0.01
- STRO 0.00
- Stochastic Oscillator
- ACET 68.33
- STRO 50.00
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.